Pfizer (PFE) stock is generating buzz with over 200 searches and expert opinions weighing in on its viability as an investment. Key points include:

• Comparative analysis with Johnson & Johnson stocks.
• Recent upgrade in price target by Guggenheim from $33 to $35 with a buy rating.
• Expert articles from Trefis and Forbes discussing which pharmaceutical giant is a better buy.

Here's the full scoop.